Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561802 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4579301 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL585441 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL875645 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL31217 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL7523852 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL3468761 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL4580141 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL875710 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 | |
| SCHEMBL876407 | 1.00 | TDP1 (0.64) | TDP1L3MBTL1CHRM2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429386-B | Synthetic method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113429386-A | Synthetic method of R-lipoic acid | 苏州富士莱医药股份有限公司 | 2021-09-24 | — | — | CN | claimed |
| JP-11035529-A | — | — | None | — | — | JP | disclosed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | MINDSET PHARMA INC. (CA) | 2026-04-21 | — | — | US | disclosed |
| EP-4704915-A1 | LINKERS FOR DRUG CONJUGATES AND ANTIBODY DRUG CONJUGATES | BioAtla, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2025-12-23 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250325491-A1 | POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | BIO TRIP B V (NL) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-0087853-A2 | 4-Diphenylmethyl-1-(oxoalkyl)imino)methyl-piperidines and their derivatives | McNeilab, Inc. (US) | 1983-09-07 | — | — | EP | disclosed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | disclosed |
| US-4370335-A | Antisecretory 4-diphenylmethyl-1-[(oxoalkyl)imino]methyl-piperidines and their derivatives | MCNEILAB, INC. (US) | 1983-01-25 | — | — | US | disclosed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | disclosed |
| EP-0043285-A1 | Method for determination of valproic acid and reagents therein | Dainippon Pharmaceutical Co., Ltd. (JP) | 1982-01-06 | — | — | EP | disclosed |
| EP-0029306-A1 | Aminoalkyl compounds, their production and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1981-05-27 | — | — | EP | disclosed |
| WO-1980001685-A1 | RADIOLABELED AMINE COMPOUNDS AND THEIR USE | BYK MALLINCKRODT CIL BV (NL) | 1980-08-21 | — | — | WO | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
| US-4167638-A | Process for production of 8-NHR quinolines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TDP1 236/4885L3MBTL1 1394/4885CHRM2 4681/4885 |
| US-12502434-B2 | Compound comprising EZH2 inhibitor and E3 ligase binder and pharmaceutical composition for preventing or treating EZH2-associated disease comprising same as active ingredient | EZH2, BMI1, SUZ12 | TDP1 3035/4885L3MBTL1 886/4885CHRM2 4736/4885 |
| US-20250325491-A1 | POLYVALENT MOLECULE BASED LIPID NANOPARTICLES FOR NUCLEIC ACID DELIVERY | POLRMT, TLR3, TLR9 | TDP1 1129/4885L3MBTL1 214/4885CHRM2 4867/4885 |
| US-12606543-B2 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto | HTR6, CNR1, HTR3C | TDP1 2032/4885L3MBTL1 2027/4885CHRM2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.